vs
Side-by-side financial comparison of NaaS Technology Inc. (NAAS) and Neuphoria Therapeutics Inc. (NEUP). Click either name above to swap in a different company.
NaaS Technology Inc. is the larger business by last-quarter revenue ($25.9M vs $15.0M, roughly 1.7× Neuphoria Therapeutics Inc.). Neuphoria Therapeutics Inc. runs the higher net margin — 75.1% vs -193.3%, a 268.3% gap on every dollar of revenue.
NaaS Technology Inc. is a leading electric vehicle energy service provider based in China. It delivers one-stop solutions covering charging network operation, software and hardware support for charging station operators, and value-added services such as charging location search and payment for EV owners, serving both enterprise and individual customers across domestic and select overseas markets.
Neuphoria Therapeutics Inc is a clinical-stage biopharmaceutical company focused on researching and developing innovative targeted therapies for unmet medical needs in neurological and psychiatric conditions, including anxiety, treatment-resistant depression, and other central nervous system disorders. Its core R&D efforts prioritize delivering safer, more effective treatment options for patient groups with limited existing care alternatives.
NAAS vs NEUP — Head-to-Head
Income Statement — Q2 FY2024 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $25.9M | $15.0M |
| Net Profit | $-50.0M | $11.3M |
| Gross Margin | 29.2% | — |
| Operating Margin | -144.2% | 79.8% |
| Net Margin | -193.3% | 75.1% |
| Revenue YoY | 121.2% | — |
| Net Profit YoY | 18.4% | — |
| EPS (diluted) | $-0.02 | $6.55 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $24.7M | $17.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-33.4M | $26.0M |
| Total Assets | $180.2M | $30.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 25 | — | $17.0M | ||
| Q2 24 | $24.7M | — |
| Q1 25 | — | $26.0M | ||
| Q2 24 | $-33.4M | — |
| Q1 25 | — | $30.7M | ||
| Q2 24 | $180.2M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-25.7M | $11.5M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | 1.02× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 25 | — | $11.5M | ||
| Q2 24 | $-25.7M | — |
| Q1 25 | — | 1.02× | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
